retatrutide mechanism triple agonist gip glp-1 glucagon Beyond GLP-1: Retatrutide's triple-agonist (GLP-1, GIP, glucagon) is redefining metabolic health. Phase 2 data shows ~24% weight loss—surpassing semaglutide & tirzepatide. Evidence-based protocols demand nutrition support alongside prescribing What GLP‑3 Really Is: Retatrutide

Its FDA approval specifically for weight loss in 2021 opened the floodgates for prescriptions to people without diabetes, a population that the studies suggest may face even higher risks for certain complications like NAION

155 However, whether this can be extrapolated to other CMRFs, and whether there is a pharmacoeconomic imperative, needs further clarification

Important safety considerations include boxed warnings for thyroid C-cell tumors (based on animal studies), and cautions regarding pancreatitis and gallbladder disease

These molecules facilitate the closure of ATP-sensitive potassium channels (K ATP ) and the opening of voltage-dependent calcium channels, causing an influx of calcium that triggers the release of insulin granules (Zheng et al., 2024)